| Basics |
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals Inc is a biotechnology company. It is engaged in the development of medicine to treat diseases such as hepatitis B, and thrombosis with a genetic origin, primarily divided by the overproduction of one or more proteins.
|
| IPO Date: |
July 6, 2000 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$5.26B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.46 | 3.24%
|
| Avg Daily Range (30 D): |
$0.78 | 2.29%
|
| Avg Daily Range (90 D): |
$0.66 | 2.87%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.79M |
| Avg Daily Volume (30 D): |
1.73M |
| Avg Daily Volume (90 D): |
1.83M |
| Trade Size |
| Avg Trade Size (Sh.): |
119 |
| Avg Trade Size (Sh.) (30 D): |
64 |
| Avg Trade Size (Sh.) (90 D): |
68 |
| Institutional Trades |
| Total Inst.Trades: |
5,101 |
| Avg Inst. Trade: |
$3.2M |
| Avg Inst. Trade (30 D): |
$4.23M |
| Avg Inst. Trade (90 D): |
$3.53M |
| Avg Inst. Trade Volume: |
.11M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$5.49M |
| Avg Closing Trade (30 D): |
$10.7M |
| Avg Closing Trade (90 D): |
$7.26M |
| Avg Closing Volume: |
182.02K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-1.1
|
$-1.26
|
$2.78
|
|
Diluted EPS
|
$-1.11
|
$-1.26
|
$2.75
|
|
Revenue
|
$ 572.98M
|
$ 27.77M
|
$ 542.71M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -159.35M
|
$ -178.65M
|
$ 367.86M
|
|
Operating Income / Loss
|
$ -107.96M
|
$ -165.55M
|
$ 381.2M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 60.39M
|
$ -55.92M
|
$
|
|
PE Ratio
|
|
|
|
| Splits |
|
Nov 17, 2011:
1:10
|
|
Jan 15, 2004:
1:65
|
|
|
|
